Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3233/JND-210699 http://scihub22266oqcxt.onion/10.3233/JND-210699 34120913!?!34120913 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34120913&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Neuromuscul+Dis 2021 ; 8 (6): 1003-1005 Nephropedia Template TP {{tp|p=34120913|t=2021. COVID-19 in a Cohort of Patients with Congenital Myasthenic Syndrome |pdf=|usr=}}{{34120913}} gab.com Text COVID-19 in a Cohort of Patients with Congenital Myasthenic Syndrome JO: J Neuromuscul Dis http://www.kidney.de/pget.php?&tw=1&pmid=34120913 #FOAvip Congenital Myasthenic Syndromes (CMS) are a rare group of genetic disorders of neuromuscular transmission. Some subtypes of CMS can be associated with respiratory and bulbar weakness and these patients may therefore be at high risk of developing a severe disease from COVID-19. We screened 73 patients with genetically confirmed CMS who were attending the UK national referral centre for evidence of previous Severe Acute Respiratory Syndrome Corona Virus 2 infection and their clinical outcome. Of 73 patients, seven had history of confirmed COVID-19. None of the infected patients developed a severe disease, and there were no signals that CMS alone carries a high risk of severe disease from COVID-19. Twit Text FOAVip COVID-19 in a Cohort of Patients with Congenital Myasthenic Syndrome ????J Neuromuscul Dis http://www.kidney.de/pget.php?&tw=1&pmid=34120913 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34120913 #FOAvip English Wikipedia <ref>{{Cite pmid|34120913}}</ref> COVID-19 in a Cohort of Patients with Congenital Myasthenic Syndrome #MMPMID34120913 Alabaf S; O'Connell K; Ramdas S; Beeson D; Palace J J Neuromuscul Dis 2021[]; 8 (6): 1003-1005 PMID34120913show ga Congenital Myasthenic Syndromes (CMS) are a rare group of genetic disorders of neuromuscular transmission. Some subtypes of CMS can be associated with respiratory and bulbar weakness and these patients may therefore be at high risk of developing a severe disease from COVID-19. We screened 73 patients with genetically confirmed CMS who were attending the UK national referral centre for evidence of previous Severe Acute Respiratory Syndrome Corona Virus 2 infection and their clinical outcome. Of 73 patients, seven had history of confirmed COVID-19. None of the infected patients developed a severe disease, and there were no signals that CMS alone carries a high risk of severe disease from COVID-19. |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |COVID-19/*complications[MESH] |Child[MESH] |Cohort Studies[MESH] |Cross-Sectional Studies[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Myasthenic Syndromes, Congenital/*complications[MESH] |Treatment Outcome[MESH] |United Kingdom[MESH]COVID-19 in a Cohort of Patients with Congenital Myasthenic Syndrome (epmc).pdf DeepDyve Pubget Overpricing